identifying individual t cell receptors of optimal avidity for tumor antigens
Clicks: 278
ID: 191464
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
278 views
63 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #301 of 644 articles by views in sudebno-meditsinskaia ekspertiza
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 644 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Cytotoxic T cells recognize, via their T cell receptors (TCRs), small antigenic peptides presented by the Major Histocompatibility Complex (pMHC) on the surface of professional antigen presenting cells (APC), and infected or malignant cells. The efficiency of T cell triggering critically depends on TCR binding to cognate pMHC, i.e. the TCR-pMHC structural avidity. The binding and kinetic attributes of this interaction are key parameters for protective T cell-mediated immunity, with stronger TCR-pMHC interactions conferring superior T cell activation and responsiveness than weaker ones. However, high avidity TCRs are not always available, particularly among self/tumor antigen-specific T cells, most of which are eliminated by central and peripheral deletion mechanisms. Consequently, systematic assessment of T cell avidity can greatly help distinguishing protective from non-protective T cells. Here, we review novel strategies to assess TCR-pMHC interaction kinetics, enabling the identification of the functionally most-relevant T cells. We also discuss the significance of these technologies in determining which cells within a naturally occurring polyclonal tumor-specific T cell response would offer the best clinical benefit for use in adoptive therapies, with or without T cell engineering.
| Reference Key |
ehebeisen2015frontiersidentifying
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Michaël eHebeisen;Mathilde eAllard;Philippe eGannon;Julien eSchmidt;Julien eSchmidt;Daniel Ernst Speiser;Daniel Ernst Speiser;Nathalie eRufer;Nathalie eRufer |
| Journal | sudebno-meditsinskaia ekspertiza |
| Year | 2015 |
| DOI |
10.3389/fimmu.2015.00582
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.